Best of the Blog: IN VIVO, March 2009

A selection of our favorite blog posts from March 2009 for stories not covered elsewhere in this month's IN VIVO.

Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In March, Windhover’s editorial staff posted 51 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Highlights included analysis of important FDA advisory committee decisions, continued coverage of Big Pharma mega-mergers, and the rollout of our weekly IN VIVO Blog Podcast. Here are a few of our favorite blog posts and excerpts for stories not covered elsewhere in this month’s IN VIVO.

(March 4.) Proposals advocating "open" or "collaborative" innovation in pharma R&D are suddenly cropping up throughout the pharma industry in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By 

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

BioBytes: AI-Related Deals In Q2 ‘25

 
• By 

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.